Teva Pharmaceutical Industries Ltd (NYSE:TEVA) was the recipient of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 65,988,772 shares, a decrease of 7.2% from the February 15th total of 71,087,326 shares. Based on an average trading volume of 12,723,380 shares, the days-to-cover ratio is currently 5.2 days.
In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 5,050 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $19.68, for a total value of $99,384.00. Following the transaction, the executive vice president now directly owns 44,517 shares of the company’s stock, valued at approximately $876,094.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders sold 10,734 shares of company stock worth $204,795. Insiders own 7.10% of the company’s stock.
Large investors have recently bought and sold shares of the business. Calton & Associates Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at about $108,000. Fieldpoint Private Securities LLC acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at about $171,000. Global Financial Private Capital LLC acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at about $193,000. Wetherby Asset Management Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at about $197,000. Finally, Sigma Planning Corp acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at about $214,000. Institutional investors and hedge funds own 58.20% of the company’s stock.
A number of brokerages have issued reports on TEVA. Vetr lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $22.63 target price on the stock. in a research report on Thursday, January 11th. ValuEngine upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 11th. Zacks Investment Research lowered shares of Teva Pharmaceutical Industries from a “hold” rating to a “sell” rating in a research report on Friday, January 12th. BTIG Research lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and set a $24.00 price target on the stock. in a research report on Thursday, January 18th. They noted that the move was a valuation call. Finally, Leerink Swann increased their price target on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “underperform” rating in a research report on Friday, January 26th. Eleven investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $19.67.
NYSE:TEVA traded down $0.34 during trading hours on Friday, reaching $16.88. The company had a trading volume of 6,183,976 shares, compared to its average volume of 9,839,103. The company has a current ratio of 0.86, a quick ratio of 0.58 and a debt-to-equity ratio of 1.91. The stock has a market capitalization of $17,164.88, a price-to-earnings ratio of 4.30, a PEG ratio of 1.47 and a beta of 0.67. Teva Pharmaceutical Industries has a twelve month low of $10.85 and a twelve month high of $33.82.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.14. The business had revenue of $5.46 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 16.43%. The business’s quarterly revenue was down 15.9% on a year-over-year basis. During the same period last year, the company posted $1.38 earnings per share. equities analysts predict that Teva Pharmaceutical Industries will post 2.3 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Short Interest in Teva Pharmaceutical Industries Ltd (TEVA) Declines By 7.2%” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/08/teva-pharmaceutical-industries-ltd-teva-short-interest-update.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.